What dosing regimen should be used to replenish serum magnesium in a 57‑year‑old woman with a magnesium level of 0.9 mg/dL?

Magnesium Repletion for Serum Magnesium 0.9 mg/dL in a 57-Year-Old Woman

For a serum magnesium of 0.9 mg/dL (0.37 mmol/L), initiate oral magnesium oxide 12–24 mmol daily (approximately 400–800 mg elemental magnesium) divided throughout the day with the largest dose at bedtime, and reserve intravenous magnesium sulfate 2 g infused over 15–20 minutes only if the patient is symptomatic or has cardiac arrhythmias. 1, 2, 3

Severity Assessment and Route Selection

A magnesium level of 0.9 mg/dL represents mild-to-moderate hypomagnesemia (normal range 1.5–2.5 mg/dL). 3 The choice between oral and intravenous replacement depends on:

• Presence of symptoms: Tetany, seizures, cardiac arrhythmias (especially torsades de pointes), or altered mental status mandate immediate IV therapy 4, 5
• Cardiac risk: Patients with QT prolongation, ventricular arrhythmias, or digoxin toxicity require urgent IV magnesium 4
• Gastrointestinal function: Malabsorption, severe diarrhea, or inability to tolerate oral intake necessitate parenteral therapy 2, 3

In an asymptomatic 57-year-old woman with no cardiac complications, oral replacement is the appropriate first-line approach. 2, 3

Oral Magnesium Replacement Protocol

Initial Dosing Strategy

• Start with magnesium oxide 12–24 mmol daily (equivalent to four 160 mg capsules, each providing approximately 4 mmol elemental magnesium) 3
• Divide doses throughout the day with the largest portion administered at bedtime to exploit slower nighttime intestinal transit and maximize absorption 2, 3
• Magnesium oxide is preferred because it provides the highest elemental magnesium content per dose and is converted to magnesium chloride in gastric acid 2, 3

Alternative Formulations

If gastrointestinal intolerance develops (diarrhea is common):

• Switch to organic salts such as magnesium citrate, aspartate, or lactate, which have superior bioavailability despite lower elemental magnesium content 3
• Magnesium chloride 5% solution (30–50 mL daily, delivering 382–450 mg elemental magnesium) is an effective alternative supported by randomized trial evidence 3
• Reduce the dose rather than discontinuing oral therapy when side effects occur 3

Monitoring and Titration

• Recheck serum magnesium in 1–2 weeks after initiating therapy to assess biochemical response 3
• Target serum magnesium >0.6 mmol/L (≈1.5 mg/dL); full normalization may not be achievable in all patients 3
• Continue long-term supplementation if ongoing magnesium losses are present (diuretics, malabsorption, renal wasting) 2

Adjunctive Therapy for Refractory Cases

If oral magnesium alone fails to normalize serum levels:

• Add alfacalcidol (1-α-hydroxycholecalciferol) 0.25 µg daily, titrating every 2–4 weeks up to a maximum of 9 µg daily 2, 3
• Monitor serum calcium regularly during vitamin D therapy to prevent hypercalcemia 2

Intravenous Magnesium Replacement (When Indicated)

Emergency Situations

For life-threatening arrhythmias (torsades de pointes, cardiac arrest):

• Administer magnesium sulfate 1–2 g IV push immediately 4, 5, 2
• This is a Class I recommendation for cardiac emergencies even when serum magnesium is normal 4
• Dilute 1–2 g in 10 mL D5W for IV/IO bolus in polymorphic ventricular tachycardia with QT prolongation 1

Non-Emergent IV Repletion

For symptomatic but non-life-threatening hypomagnesemia:

• Infuse magnesium sulfate 2 g in 50 mL over 15–20 minutes 1
• Maximum infusion rate is 150 mg per minute; therefore a 2 g dose requires at least 13–15 minutes 1
• Repeat doses may be needed every 6–12 hours, as serum magnesium drops below 2.0 mg/dL within 12–24 hours after a single 2 g dose 6

Maintenance IV Therapy

For patients requiring ongoing parenteral support:

• Add 4–12 mmol magnesium sulfate to IV saline infusions for less urgent correction 2
• Subcutaneous administration (0.5–1 L saline with 4 mmol magnesium) can be given 1–3 times weekly for intermittent therapy 2

Electrolyte Interactions and Concurrent Management

Potassium Correction

• Low magnesium impairs potassium retention and can cause refractory hypokalemia 7
• Assess and correct potassium concurrently, targeting serum potassium ≥4.0 mmol/L 4, 2
• Magnesium repletion improves potassium balance even when serum potassium appears normal; in one randomized trial, magnesium-treated patients achieved positive potassium balance (+72 mmol) versus negative balance (−74 mmol) in controls despite similar serum potassium levels 7

Calcium Assessment

• Check serum calcium because hypomagnesemia impairs parathyroid hormone signaling and can cause hypocalcemia 3
• In patients with QT prolongation and torsades de pointes, target magnesium ≥2.0 mmol/L (≈4.8 mg/dL) and potassium ≥4.0 mmol/L 4, 2

Safety Considerations and Adverse Effects

Oral Magnesium

• Diarrhea is the most common side effect of oral magnesium salts; dose reduction or formulation change is preferred over discontinuation 2, 3
• Avoid in severe renal insufficiency or reduce dose significantly 8
• Contraindicated in constipation-prone patients when using magnesium oxide; however, this is context-dependent as magnesium oxide is used therapeutically for constipation 8, 9

Intravenous Magnesium

• Hypermagnesemia (>2.2 mEq/L) can cause bradycardia, hypotension, respiratory depression, and cardiac arrest 2
• Monitor for CNS toxicity: altered speech, consciousness, areflexia progressing to respiratory depression 1
• Risk is very small with standard doses of 1–2 g IV used for torsades de pointes 4

Common Pitfalls and How to Avoid Them

1. Failing to identify ongoing losses: Always assess for diuretic use, gastrointestinal losses, or renal wasting before initiating therapy; rehydration to correct secondary hyperaldosteronism is the most important first step in patients with high stomal output or diarrhea 2, 3

2. Inadequate dosing frequency: A single 2 g IV dose maintains serum magnesium above 2.0 mg/dL for less than 12 hours on average; expect to administer IV magnesium at least twice daily for sustained effect 6

3. Ignoring refractory hypokalemia: Magnesium deficiency must be corrected to restore normal potassium homeostasis; potassium supplementation alone will be ineffective 7

4. Premature discontinuation due to diarrhea: Switch formulations or reduce dose rather than stopping oral therapy entirely 3

5. Overlooking cardiac risk: Even mild hypomagnesemia can precipitate arrhythmias in patients on QT-prolonging medications or with underlying cardiac disease; maintain a lower threshold for IV repletion in these populations 4, 5